Hodgkin's disease. Treatment of resistant patients

M. De Lena, A. Santoro

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This paper summarizes the preliminary results obtained at the Istituto Nazionale Tumori of Milan with a new multiple-agent chemotherapy (ABVD) specifically designed in 1973 to serve as an alternative treatment for MOPP failures. Thirty patients were suitable for the evaluation of response after secondary treatment. Twenty-one patients were previously treated with MOPP and nine with ABVD. Although based on a limited series, the findings indicate that ABVD is effective in producing significant response in about two-thirds of patients resistant to primary MOPP chemotherapy. Since secondary MOPP treatment induced objective response, though of limited magnitude and duration in ABVD failures, we can conclude that no cross-resistance exists between the two combinations. This is also supported by markedly improved median survival observed in patients achieving complete remission.

Original languageEnglish
Pages (from-to)83-85
Number of pages3
JournalCancer Clinical Trials
Volume2
Issue number1
Publication statusPublished - 1979

Fingerprint

Hodgkin Disease
Drug Therapy
Therapeutics
Treatment Failure
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hodgkin's disease. Treatment of resistant patients. / De Lena, M.; Santoro, A.

In: Cancer Clinical Trials, Vol. 2, No. 1, 1979, p. 83-85.

Research output: Contribution to journalArticle

@article{df06b78126b643d387f71854072bf990,
title = "Hodgkin's disease. Treatment of resistant patients",
abstract = "This paper summarizes the preliminary results obtained at the Istituto Nazionale Tumori of Milan with a new multiple-agent chemotherapy (ABVD) specifically designed in 1973 to serve as an alternative treatment for MOPP failures. Thirty patients were suitable for the evaluation of response after secondary treatment. Twenty-one patients were previously treated with MOPP and nine with ABVD. Although based on a limited series, the findings indicate that ABVD is effective in producing significant response in about two-thirds of patients resistant to primary MOPP chemotherapy. Since secondary MOPP treatment induced objective response, though of limited magnitude and duration in ABVD failures, we can conclude that no cross-resistance exists between the two combinations. This is also supported by markedly improved median survival observed in patients achieving complete remission.",
author = "{De Lena}, M. and A. Santoro",
year = "1979",
language = "English",
volume = "2",
pages = "83--85",
journal = "Cancer Clinical Trials",
issn = "0190-1206",
publisher = "Masson Publishing",
number = "1",

}

TY - JOUR

T1 - Hodgkin's disease. Treatment of resistant patients

AU - De Lena, M.

AU - Santoro, A.

PY - 1979

Y1 - 1979

N2 - This paper summarizes the preliminary results obtained at the Istituto Nazionale Tumori of Milan with a new multiple-agent chemotherapy (ABVD) specifically designed in 1973 to serve as an alternative treatment for MOPP failures. Thirty patients were suitable for the evaluation of response after secondary treatment. Twenty-one patients were previously treated with MOPP and nine with ABVD. Although based on a limited series, the findings indicate that ABVD is effective in producing significant response in about two-thirds of patients resistant to primary MOPP chemotherapy. Since secondary MOPP treatment induced objective response, though of limited magnitude and duration in ABVD failures, we can conclude that no cross-resistance exists between the two combinations. This is also supported by markedly improved median survival observed in patients achieving complete remission.

AB - This paper summarizes the preliminary results obtained at the Istituto Nazionale Tumori of Milan with a new multiple-agent chemotherapy (ABVD) specifically designed in 1973 to serve as an alternative treatment for MOPP failures. Thirty patients were suitable for the evaluation of response after secondary treatment. Twenty-one patients were previously treated with MOPP and nine with ABVD. Although based on a limited series, the findings indicate that ABVD is effective in producing significant response in about two-thirds of patients resistant to primary MOPP chemotherapy. Since secondary MOPP treatment induced objective response, though of limited magnitude and duration in ABVD failures, we can conclude that no cross-resistance exists between the two combinations. This is also supported by markedly improved median survival observed in patients achieving complete remission.

UR - http://www.scopus.com/inward/record.url?scp=0018767627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018767627&partnerID=8YFLogxK

M3 - Article

C2 - 93032

AN - SCOPUS:0018767627

VL - 2

SP - 83

EP - 85

JO - Cancer Clinical Trials

JF - Cancer Clinical Trials

SN - 0190-1206

IS - 1

ER -